BC Platforms launches BC Catalyst, first-to-market, AI-native analytics product that accelerates precision medicine
BC Catalyst transforms genomic and real-world data into fast, actionable insights to advance precision medicine at scale.
Expert support and insights to fuel research, development, and commercialization.
Whether preparing for a clinical submission, evaluating realโworld outcomes, or developing market access evidence, our expert team provides the clarity, rigor, and confidence you need to succeed.
Accelerate your path from feasibility to submission using evidence spanning study design, analysis, and regulatory preparation.
Strengthen your evidence base by tapping into our deep expertise in epidemiology, biostatistics, key therapeutic areas, and HEOR / HTA.
Reduce operational burden through comprehensive service packages, including study protocols, statistical analysis plans, eCRF design, data management, reports, and more.
Improve decision making with analytics and standardized datasets (CDISC, OMOP or custom models, supported by compliance review), anonymized imaging solutions, and exploratory data modeling.
Our highly experienced team applies decades of handsโon scientific, clinical, and technical expertise to keep your projects moving faster and with less risk โ delivering consistently highโquality results.
BC Catalyst transforms genomic and real-world data into fast, actionable insights to advance precision medicine at scale.
We welcome Keith Collier as Chief Product Officer and Michele Lichtenfield as EVP and Head of Global Marketing.
We join BRECISE, a major cancer research initiative advancing biomarker development to improve diagnosis, treatment and personalized care across Europe.
Contact us to learn more about our solutions or discuss how we can support your needs.